Author: Ross D. Overacker; Somdev Banerjee; George F. Neuhaus; Selena Milicevic Sephton; Alexander Herrmann; James A. Strother; Ruth Brack-Werner; Paul R. Blakemore; Sandra Loesgen
Title: Biological Evaluation of Molecules of the azaBINOL Class as Antiviral Agents: Specific Inhibition of HIV-1 RNase H Activity by 7-Isopropoxy-8-(naphth-1-yl)quinoline Document date: 2019_1_23
ID: m2zw8eq4_14
Snippet: The single round infectivity assay using HIV-1 enveloped pseudotyped viruses is able to 195 report on inhibition of early stages of infection including cell entry, reverse transcription, and 196 integration steps. The active azaBINOL compound B#24 inhibited all HIV-1 strains tested 197 regardless of their differing viral tropism (HXB2, YU2, and 89.6). This broad inhibition 198 indicated that the antiviral mode-of-action is unlikely to rely on the.....
Document: The single round infectivity assay using HIV-1 enveloped pseudotyped viruses is able to 195 report on inhibition of early stages of infection including cell entry, reverse transcription, and 196 integration steps. The active azaBINOL compound B#24 inhibited all HIV-1 strains tested 197 regardless of their differing viral tropism (HXB2, YU2, and 89.6). This broad inhibition 198 indicated that the antiviral mode-of-action is unlikely to rely on the viral fusion process, as 199 changing the surface glycoprotein does not affect antiviral activity. Additionally, the EASY-HIT temsavir, which loses activity if dosed post viral entry. Instead, B#24 remains active throughout 207 the assay, but exhibits a subtle decrease in antiviral activity between 6-8 hours post infection. 208
Search related documents:
Co phrase search for related documents- action antiviral mode and antiviral mode: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- action antiviral mode and cell entry: 1
- action antiviral mode and early stage: 1
- action antiviral mode and post infection: 1
- action antiviral mode and viral entry: 1, 2, 3, 4, 5
- active azaBINOL compound and antiviral activity: 1
- active azaBINOL compound and azaBINOL compound: 1
- active remain and cell entry: 1
- active remain and viral entry: 1, 2
- activity lose and antiviral activity: 1
- activity lose and post infection: 1
- activity lose and viral entry: 1
- antiviral activity and azaBINOL compound: 1, 2
- antiviral activity and broad inhibition: 1, 2, 3, 4, 5
- antiviral activity and cell entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
- antiviral activity and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- antiviral activity and fusion process: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral activity and hour post infection: 1
- antiviral activity and infectivity assay: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date